The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

With greater clinical severity, they recommend adding a long-acting muscarinic receptor antagonists (LAMA) to ICS + long-acting b2 agonist (LABA) combination for 'triple therapy'. In even more ...

An early study with chimeric receptors between the alpha2c-adrenergic receptor and m3-muscarinic receptor suggested the possible heterodimerization between GPCR types. Direct evidence for GPCR ...

Our recent work (McQuail & Burk, 2006) suggests that cholinergic muscarinic receptors, particularly the muscarinic M1 receptor, are important for mediating the effects of the cortical acetylcholine on ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator ... an already-approved muscarinic antagonist designed to reduce M1/M4-related side effects in the peripheral nervous ...

Muscarinic receptors are involved with neurotransmission via acetylcholine and glutamate, and are hypothesised to be dysfunctional in schizophrenia. Most drugs developed to treat schizophrenia to ...

It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to ...